08.21.25 -- Heart-In-A-Jar Organ Model Earns Regulatory Respect After 25 Years In The Making

Gain insight into why certain regions offer strategic advantages, from regulatory flexibility to faster enrollment, and how to effectively integrate them into your development strategy.

Project Optimus represents a transformative shift in oncology, advocating for a more nuanced, evidence-based approach to dose selection, prioritizing patient safety alongside treatment effectiveness.

Amid scrutiny of the financial conflicts of interest in biomedical research, new federal rules aim to improve transparency and preserve the integrity of publicly funded research.

Most clinical trials overlook one crucial factor: giving sites and patients a voice in how studies are run. That’s starting to change—and the impact is significant.

Leveraging incurred sample reanalysis (ISR) in your quality control helps your team mitigate risks, establish regulatory compliance, and instill confidence in your pharmacokinetic modeling.

As sponsors strive to deliver therapies with increasing efficiency, CDMOs are poised to remain vital, offering specialized expertise, accelerated timelines, cost efficiency, and risk mitigation.

Leveraging over 140 completed neuroscience studies and specialized knowledge in neurodegenerative diseases, TFS delivers substantial expertise and a demonstrated history of successful trials.